Edition:
United Kingdom

Kamada Ltd (KMDA.OQ)

KMDA.OQ on NASDAQ Stock Exchange Global Select Market

4.53USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,670
52-wk High
$8.55
52-wk Low
$3.75

Summary

Name Age Since Current Position

Leon Recanati

67 2013 Chairman of the Board

Amir London

46 2015 Chief Executive Officer

Gil Efron

51 2015 Deputy Chief Executive Officer, Chief Financial Officer

David Tsur

67 2015 Deputy Chairman of the Board

Ruth Wolfson

69 2015 Senior Vice President - Scientific Affairs

Barak Bashari

51 2012 Vice President - Operations

Shani Dotan

42 2013 Vice President - Human Resources

Yael Brenner

52 2015 Vice President - Quality

Orit Pinchuk

50 2014 Vice President - Regulatory Affairs and Quality R&D

Eran Schenker

53 2015 Vice President - Medical Director

Michal Stein

2017 Vice President and Medical Director for Immunology

Pnina Strauss

41 2015 Vice President - Inhalation programs & IP

Naveh Tov

2016 Vice President-Clinical Development and Medical Director for Pulmonary Diseases

Liliana Bar

60 2012 Vice President - Research & Development

Michael Berelowitz

71 2015 Director

Jonathan Hahn

33 2010 Director

Gwen Melincoff

64 2017 Director

Estery Giloz-Ran

42 2014 Independent Director

Abraham Havron

70 2011 Independent Director

Tuvia Shoham

71 2007 Independent Director

Biographies

Name Description

Leon Recanati

Mr. Leon Yehuda Recanati is Chairman of the Board of the company. He has served on our board of directors since May 2005 and has served as Chairman since March 7, 2013. Mr. Recanati currently serves as a board member of Evogene Ltd., a plant genomics company listed on the TASE and New York Stock Exchange. He is also a board member of the following private companies: GlenRock Israel Ltd., GlenRock Medical, Shellcase, Gov, Govli Financial Services Ltd., Govli Limited, Microbes Inc., RelTech Holdings Ltd., Legov Ltd., Insight Capital Ltd., Shavit Capital Fund and Newbank Ltd. He is currently Chairman and Chief Executive Officer of GlenRock. Previously, Mr. Recanati was Chief Executive Officer and/or Chairman of IDB Holding Corporation; Clal Industries Ltd.; Azorim Investment Development and Construction Co Ltd.; Delek Israel Fuel Corporation; and Super-Sol Ltd. He also founded Clal Biotechnologies Industries Ltd., a biotechnology investment company operating in Israel. Mr. Recanati holds an MBA degree from the Hebrew University of Jerusalem and Honorary Doctorates from the Technion Institute of Technology and Tel Aviv University.

Amir London

Mr. Amir London is Chief Executive Officer of the company. Since July 2015. Prior to that, he has served as our Senior Vice President, Business Development. Mr. London brings with him over 20 years of senior management and international business development experience. Prior to joining Kamada , Mr. London was the COO of Fidelis Diagnostics, a US-based provider of innovative in-office medical diagnostic services. Earlier in his career Mr. London was the CEO of Promedico, a leading Israeli-based $350 million healthcare distribution company, and the General Manager of Cure Medical, providing contract manufacturing services for clinical studies, as well as home-care solutions. Before that, for 10 years, Mr. London was a Partner with Tefen, an international publicly-traded operations management consulting firm, responsible for the firm's global biopharma practice. Mr. London holds a B.Sc. in Industrial and Management Engineering from the Technion in Haifa, Israel.

Gil Efron

Mr. Gil Efron will no longer serve as Deputy Chief Executive Officer and Chief Financial Officer at Kamada Ltd effective December 31, 2017. He has held both roles since July 2015 and the latter role since September 28, 2011. He has over 20 years of experience in various finance management positions. Mr. Efron is also currently the owner and Chief Executive Officer of GEO Consulting Ltd. which he founded in February 2011 and provides financial management services. From February 2006 until 2011, Mr. Efron served as Chief Financial Officer of RRSat Global Communications Ltd. (Nasdaq: RRST), a provider of distribution and content management services for television and radio broadcasting networks. Prior to that, he served in various finance positions, including as Chief Financial Officer of Proficiency Ltd., as Chief Financial Officer of IP Planet Network Ltd. and as a senior auditor with the Israeli member firm of PricewaterhouseCoopers. Mr. Efron also served as Director of Poalim Ventures I Ltd. He holds a Bachelors degree in Accounting and Economics and a MBA degree, both from the Hebrew University of Jerusalem. He is a Certified Public Accountant.

David Tsur

Mr. David Tsur is Deputy Chairman of the Board of the company. He is the Co-founder of Kamada and served has our Chief Executive Officer and on our board of directors since the company's inception in 1990 until July 2015. Currently he serves as our Active Deputy Chairman of the Board. Prior to co-founding Kamada, Mr. Tsur was Chief Executive Officer of Arad Systems and RAD Chemicals Inc. He has also held various positions in the Israeli Ministry of Economy (formerly named the Ministry of Industry and Trade), including Chief Economist and Commercial Attaché in Argentina and Iran. Mr. Tsur holds a BA degree in Economics and International Relations and an MBA in Business Management from the Hebrew University of Jerusalem

Ruth Wolfson

Dr. Ruth Wolfson is Senior Vice President - Scientific Affairs of Kamada Ltd. since January 2015. He has served as our Senior Vice President, Quality and Regulatory Affairs since 2004. She has more than 15 years of experience in regulatory affairs, including submissions to the FDA, EMA and the Health Protection Branch in Canada. From 1989 to 2004, she served as Head of Regulatory Affairs at InterPharm Laboratories Ltd., a biopharmaceutical corporation. Ms. Wolfson holds a BSc degree in Agriculture and an MSc degree in Biochemical Agriculture, both with distinction, from the Hebrew University of Jerusalem, as well as a PhD from the Weizmann Institute’s Department of Biochemistry.

Barak Bashari

Mr. Barak Bashari is Vice President, Operations of Kamada Ltd. since September 2, 2012. He has served as our Vice President, Operations and Plant Manager since September 2012. Mr. Bashari has 17 years of experience in pharmaceuticals operations in various positions. Prior to joining us, from October 2004 to August 2012, he was the Executive Director of Teva Pharmaceutical Industry Ltd.’s three sterile plants in Israel. Mr. Bashari holds a BSc degree in Mechanical Engineering from the Technion-Israeli Institute of Technology (Haifa) and an MSM degree from the New York Polytechnic University

Shani Dotan

Ms. Shani Dotan is Vice President - Human Resources of Kamada Ltd. She has served as our Vice President, Human Resources since Nov 2013. Mrs. Dotan has more than a decade of expertise in local and global organizations and in all HR aspects. Prior to joining us, she served as the Human Resources Manager at Teva Pharmaceuticals at the Plant in Jerusalem. Mrs. Dotan holds an MA degree in Psychology and a BA degree in Behavioral Science, both from Ben-Gurion University

Yael Brenner

Ms. Yael Brenner serves as Vice President-Quality of the company. She has served as our Vice President, Regulatory Affairs & Quality R&D since October, 2014. Mrs. Pinchuk has experience of more than 20 years in the pharmaceutical industry, fulfilling key positions that cover, among others, disciplines of Regulatory Affairs and Compliance. Prior to her joining Kamada, her last positions in Teva Pharmaceuticals Industries were Director of Compliance and RA, Operation IL and Sr. Director RA, R&D and Operation IL. She has extensive experience with FDA, EMA and CANADA Health Authorities. Mrs. Pinchuk holds B.Tech. in Textile Chemistry from Shenkar College for Engineering and Design and M.Sc. in Applied Chemistry from Jerusalem Hebrew University.

Orit Pinchuk

Ms. Orit Pinchuk is Vice President-Regulatory Affairs and Quality Research & Development at Kamada Ltd. She has served as our Vice President, Regulatory Affairs & Quality R&D since October, 2014. Mrs. Pinchuk has experience of more than 20 years in the pharmaceutical industry, fulfilling key positions that cover, among others, disciplines of Regulatory Affairs and Compliance. Prior to her joining Kamada, her last positions in Teva Pharmaceuticals Industries were Director of Compliance and RA, Operation IL and Sr. Director RA, R&D and Operation IL. She has extensive experience with FDA, EMA and CANADA Health Authorities. Mrs. Pinchuk holds B.Tech. in Textile Chemistry from Shenkar College for Engineering and Design and M.Sc. in Applied Chemistry from Jerusalem Hebrew University.

Eran Schenker

Dr. Eran Schenker is Vice President - Medical Director at Kamada Ltd. He has served as our VP Medical Director since March 2015. Dr. Schenker has 20 years of experience as international medical affairs and business development for biotechnology and pharmaceutical companies. Prior to joining us, from 2007 to 2014, Dr. Schenker worked at Neurim pharmaceuticals, where he initially served as the medical director and business development and later as vice president and completed the launch of the company's flag CNS product in more than 40 countries. Earlier in his career, from 2005 to 2006, Dr. Schenker served as the CEO and Medical Director of Collplant LTD. (TASE:CLPT) preparing the company, who developed plant driven recombinant genetically modified biomaterials technology for produces with human collagen, for an IPO. From 1995 to 2005 Dr. Schenker served as the CEO and Medical Director in Medic Touch Ltd., Mainly involved in designing and implementing the clinical plan, customer care and medical affairs systems. Dr. Schenker graduate B. Med. Sc. and holds Medical Doctor degree (M.D), from the School of Medicine at the Ben Gurion University, in Israel.

Michal Stein

Ms. Michal Stein is Vice President and Medical Director for Immunology of the company. She brings over 15 years of experience in the healthcare industry, including 12 years in increasingly senior positions at multi-national pharmaceutical companies in Israel. Prior to joining Kamada, she served for four years as Medical Director at Sanofi. In this position, Dr. Stein led the medical affairs and pharmacovigilance departments of the Israeli unit of the company, overseeing all aspects of product life-cycle management. From 2009 through 2013, Dr. Stein held multiple positions of increasing responsibility at Merck Sharp & Dohme, including Pharmacovigilance Country Lead, Medical & Scientific Liaisons Team Leader and Medical Affairs Manager, with expertise in vaccines, women's health and HIV. From 2005 through 2009, she served as Medical Affairs Manager, with expertise in oncology, at Roche Pharmaceuticals. Prior to that, from 2001 through 2005, Dr. Stein was a practicing physician in Israel, first at Rabin Medical Center, Belinson Campus, and then at Schneider Children's Medical Center. Dr. Stein holds an M.D. from the Tel-Aviv Sackler Faculty of Medicine.

Pnina Strauss

Ms. Pnina Strauss is Vice President - Inhalation programs & IP of the company. Since July 2015. Prior to that, Ms. Strauss had served as our Vice President, Clinical Development & IP since 2012. Ms. Strauss has over 10 years of experience in the pharmaceutical industry, fulfilling key positions that cover, among others, disciplines of regulatory affairs and business development. Ms. Strauss holds a BSc degree in Biochemistry and Food Sciences from the Hebrew University in Jerusalem and an MBA degree from the University of Derby.

Naveh Tov

Dr. Naveh Tov has been appointed Vice President-Clinical Development and Medical Director for Pulmonary Diseases and will lead the Company's clinical development activities at Kamada Ltd. effective July 1, 2016. He has served as Medical Director in a part-time consultancy role since 2007. He has held both active hospital academic and clinical positions at Bnai Zion Medical Center, Haifa, Israel. He specializes in Internal, Pulmonary and Sleep Medicine and served as Head of the Pulmonary Unit, and as Deputy of Internal Ward C, at Bnai Zion Medical Center, for 14 years. During these years, Dr. Tov served in academia and held appointments at the Bruce Rappoport School of Medicine-The Technion – Israel Institute of Technology. Dr. Tov holds a Doctorate of Medicine degree and a PhD degree in Medicine from the Bruce Rappoport Faculty of Medicine, from The Technion – Israel Institute of Technology.

Liliana Bar

Dr. Liliana Bar serves as Vice President - Research & Development at Kamada Ltd. She has served as our Vice President, Research and Development since June 2012. Prior to joining us, she was Director of the Development and Base Business Unit and Manager of the Development and Base Unit of Omrix from 2007. Dr. Bar holds a MSc degree and PhD in Applied Chemistry from the Hebrew University of Jerusalem and was a Research Associate at the Biochemistry Department at Hadassah Medical School at the Hebrew University of Jerusalem and a Research Associate at the Biochemistry Department of University of Virginia.

Michael Berelowitz

Dr. Michael Berelowitz has been appointed Director at Kamada Ltd effective August 4, 2015. Dr. Berelowitz has over 40 years of clinical development and academic research experience, including 5 years of pharmaceutical development experience with Pfizer, Inc. Prior to that, Dr. Berelowitz spent a number of years in academia and has held appointments at the University of Chicago, University of Cincinnati College of Medicine, SUNY at StonyBrook and, most recently, Mount Sinai School of Medicine. Dr. Berelowitz serves as a biopharmaceuticals consultant. He holds Directorship Oramed Pharmaceuticals, Recro Pharma, Inc. and DIR Technologies. Additionally, Dr. Berelowitz has served on the Board of Directors of the American Diabetes Association, the Endocrine Fellows Foundation, the Clinical Initiatives Committee of the Endocrine Society, Metacure, Ltd., Haptocure, Ltd., and has chaired the Task Force on Research of the New York State Council on Diabetes.Dr. Berelowitz completed his medical degree, residency training in Pathology, Nuclear Medicine and Internal Medicine and fellowship training in Endocrinology and Metabolism at the University of Cape Town.

Jonathan Hahn

Mr. Jonathan Hahn is Director of the company. He has served on our board of directors since March 2010. Mr. Hahn is currently the President and a director of Tuteur. Previously, Mr. Hahn held a business development position in Forest Laboratories, Inc., based in New York. Mr. Hahn holds a BA degree from San Andrés University and an MBA degree from New York University — Stern School of Business, with specializations in Finance and Entrepreneurship.

Gwen Melincoff

Ms. Gwen A. Melincoff serves as Director of the Company. Ms. Melincoff is currently an advisor to Phase 1 Ventures, an accelerator start-up program, and Verge Genomics, a privately-held life sciences company focused on the discovery and development of treatments for neurodegenerative diseases. From August 2014 to September 2016, she served as Vice President of Business Development at BTG International Inc., a UK-based specialist healthcare company. From 2004 to 2013, Ms. Melincoff was Senior Vice President of Business Development at Shire Pharmaceuticals. Additionally, from 2010 to 2013, she led the company's Strategic Investment Group (SIG). Prior to joining Shire, Ms. Melincoff held managerial and business development positions at various pharmaceutical companies, including Adolor Corporation. Ms. Melincoff has served as a board member/board observer at Tobira Therapeutics (acquired by Allergan), DBV Technologies, AM Pharma, ArmaGen Technologies, Promethera Biosciences, Naurex Inc. (acquired by Allergan), and Enterome.

Estery Giloz-Ran

Dr. Estery Giloz-Ran serves as Independent Director at Kamada Ltd. She has served on our board of directors since January 2014 and is an external director within the meaning of the Companies Law. During 2013 Dr. Giloz-Ran was a Visiting Scholar at the New York University in the Department of Accounting, as well as a Visiting Assistant Professor of Finance in the Sy Syms School of Business at the Yeshiva University in New York City. From 2010 to 2014, Dr. Giloz-Ran was also the Head of Accountancy at the Peres Academic Center in the Accounting and Business Administration Department and a lecturer at Ben-Gurion University, teaching courses in finance, taxes and accounting. From 2008 to 2010, Dr. Giloz-Ran was a tax consultant and tax capital investment law adviser at Intel Corporation in Israel. Dr. Giloz-Ran holds a PhD in tax and accounting and an M.B.A. degree, both from Ben Gurion University, and a B.A. degree in Business Management from the Open University. Dr. Giloz-Ran completed her Post-Doctorate as Visiting Scholar at New York University in the Leonard N. Stern School of Business in 2014. Dr. Giloz-Ran in a certified public accountant (Israel).

Abraham Havron

Dr. Abraham Havron serves as Independent Director of Kamada Ltd. since March 13, 2011. From 2005 to 2014, Dr. Havron has served as the Chief Executive Officer and a director of PROLOR Biotech Ltd., which in 2013 merged with OPKO Health Inc. Dr. Havron is a 35-year veteran of the biotechnology industry and was a member of the founding team and Director of Research and Development of Interpharm Laboratories Ltd. (a subsidiary of Merck Serono S.A.) from 1980 to 1987. Dr. Havron served as Vice-President Manufacturing and Process-Development of BioTechnology General Ltd., based in Rehovot, Israel (now, a subsidiary of Ferring Pharmaceuticals) from 1987 to 1999; and Vice President and Chief Technology Officer of Clal Biotechnology Industries Ltd. from 1999 to 2003. Since 2014, Dr. Havron has also served on the board of directors of MediWound Ltd. (Nasdaq: MDWD) and Enlivex Theraputics Ltd., a private company. Dr. Havron holds a Bachelor of Science degree in Chemistry and Physics and a Master of Science degree in Organic Chemistry, both from The Hebrew University of Jerusalem, and a Doctorate of Science degree in Biochemistry from Weizmann Institute of Science.

Tuvia Shoham

Mr. Tuvia Shoham serves as Independent Director at Kamada Ltd. He has served on our board of directors since May 2007 and is an independent director within the meaning of the Companies Law. Mr. Shoham is a member of the board of directors of Shachak & Co., a private real estate company. Mr. Shoham has extensive experience as a financial consultant for companies in various industry sectors, including managing a wide range of financial arrangements and advising businesses on recovery and privatization plans. Mr. Shoham was previously a partner with the Israeli member C.P.A firm of PricewaterhouseCoopers, and served as Kamada’s accountant for many years. He is a certified public accountant in Israel and also holds a BA and an MBA degree from the Hebrew University in Jerusalem.